Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Unknown 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Prolymphocytic, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Myeloid, Acute 2Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU 1Stomach Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid 1Leukemia, Large Granular Lymphocytic 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 18Rituximab 10fludarabine 8ibrutinib 6fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 5Radiotherapy 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Cyclosporine 4Chlorambucil 4Antilymphocyte Serum 4Antigens, CD19 4Valproic Acid 3Sensitivity and Specificity 3Indium 3Immunotherapy, Adoptive 3Busulfan 3Alemtuzumab 3venetoclax 2sargramostim 2obinutuzumab 2navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 2epratuzumab 2Tacrolimus 2Radioimmunodetection 2Psychiatric Rehabilitation 2Pentostatin 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Leukemia, Lymphocytic, Chronic, B-Cell × Sensitivity and Specificity × Clear all
NCT02892695 2016-12-06

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02819583 2016-10-25

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02851589 2016-08-01

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡